Cagrilintide 10mg is a synthetic long-acting analog of amylin (islet amyloid polypeptide), supplied by Echo Peptides strictly for laboratory, in-vitro research use. Structurally, it is N-terminally acylated with a γ-glutamyl linker and a C20 fatty diacid moiety, a modification that extends its plasma half-life and makes it a useful reference compound in long-duration exposure models.
As a reference agonist, cagrilintide acts at two receptor systems in parallel: the amylin receptor (AMYR) and the calcitonin receptor (CTR), placing it in the dual amylin and calcitonin receptor agonist (DACRA) class. In published research settings it has been used to probe central satiety circuitry in the area postrema and other hindbrain regions, as well as gastric emptying and postprandial glucagon signaling. Researchers study these mechanisms in cell-culture and preclinical models of energy balance, and in combination-agonist paradigms alongside incretin analogs such as semaglutide.
Key research areas
- Satiety signaling and appetite-regulation models
- Dual AMYR and CTR (DACRA) receptor activation and binding studies
- Metabolic-control and energy-balance pathways
- Combination-agonist research alongside incretin analogs (e.g., semaglutide)
Specifications
- Amount: 10mg
- Form: Lyophilized white powder
- Structure: Long-acting amylin analog; N-terminally acylated with a γ-glutamyl linker and a C20 fatty diacid moiety
- Storage: Refrigerate at 2–8°C
- Testing: Third-party tested for identity and purity; a Certificate of Analysis is available on request
This product is intended exclusively for in-vitro laboratory research. It is not for human or veterinary use, and not for diagnostic or therapeutic purposes.
